Incidental prostate cancer


  • I.M. Antonyan Kharkiv Medical Academy of Postgraduate Education, Ukraine
  • V.V. Megera Kharkiv Medical Academy of Postgraduate Education, Ukraine
  • G.G. Khareba Kharkiv Medical Academy of Postgraduate Education, Ukraine
  • O.N. Gegliuk Kharkiv Medical Academy of Postgraduate Education, Ukraine
  • V.Y. Bielov Kharkiv Medical Academy of Postgraduate Education, Ukraine



incidental prostate cancer, TURP, prostatic adenomectomy


Aim: to study the incidence of incidental prostate cancer at the point of various surgical approaches, and to compare with average world incidence. It was determined that frequency of incidental prostate cancer (IPC) diagnosis has been rising along with amount of TURP done. While over the time frame of 1996–2001 the IPC incidence was 5.9%, and in the years of 2003–2007 it was 6.3%, for the period 2012–2015 it reached the level of 10.5%. Over the years 1996–2001 the incidence of IPC was higher among the patients who underwent the open surgery (6.4%) compared to TURP group (2.3%). In the period starting 2003 and including 2007 the incidence of IPC was 8.9% in the group of prostatic adenomectomy and 6.3% for the TURP group. Starting from 2012 up to and including 2015 the incidence of IPC reached 5.9% for the open surgery group and 10.5% for the TURP group. The overall prevalence of IPC in the MHI “Regional Clinical Center of Urology and Nephrology n.a. Shapoval V.I.” starting from the year 1996 and over 2015 raised from 2.3% up to 10.5% which is similar to average world levels. As such, we can state that Ukrainian specialized urological healthcare facility demonstrates the high quality of screening of the hospitalized patients with prostate diseases in regards of early stage prostate cancer diagnosis.


United States Cancer Statistics: 1999-2006 Incidence and Mortality Web-based Report. Atlanta (GA): Department of Health and Human Services, Centers for Disease Control and Prevention, and National Cancer Institute, 2010.

Arnold M., Karim-Kos H.E., Coebergh J.W. et al. Recent trends in incidence of five common cancers in 26 European countries since 1988: Analysis of the European Cancer Observatory // Eur. J. Cancer. – 2013.

Бюлетень Національного канцер-реєстру № 14 . Рак в Україні, 2011–2012. – Київ, 2013.

Бюлетень Національного канцер-реєстру № 16. Рак в Україні, 2013–2014. – Київ, 2015.

Lawrentschuk N., Haider M.A., Daljeet N. et al. Prostaticevasive anterior tumours: the role of magnetic resonance imaging // BJU Int. – 2010. – V. 105, N 9. – P. 1231–1236.

Mottet N., Bellmunt J., Briers E. et al. Guidelines on Prostate Cancer. – 2015.

Stillwell T.J., Malek R.S., Engen D.E., Farrow G.M. Incidental adenocarcinoma after open prostatic adenectomy // J. Urol. – 1989. – V. 141. – P. 76–78.

Jonathan I., Epstein, M.D. Cancer detected incidental to simple prostatectomy (stage A1) // J. Cell. Biochem. Suppl. – 1992. – V. 16. – P. 78–82.

VanAndel G., Vleeming R., Kurth K., de Reijke T.M. Incidental carcinoma of the prostate // Semin. Surg. Oncol. – 1995. – V. 11, N 1. – P. 36–45.

Tombal B., DeVisccher L., Cosyns J.P. et al. Assessing the risk of un suspected prostate cancer in patients with benign prostatic hypertrophy: a 13-year retrospective study of the incidence and natural history of T1a-T1b prostate cancers // BJU Int. – 1999. – V. 84, N 9. – P. 1015–1020.

Kien T., Phillip A., Jerome G., D. Garth Perkins., John P. Incidental Prostatic Adenocarcinomas and Putative Premalignant Lesions in TURP Specimens Collected Before and After the Introduction of Prostrate-Specific Antigen Screening // Archives of Pathology and Laboratory Medicine. – 2000. – V. 124, N 10. – P. 1454–1456.

Zigeuner R.E., Lipsky K., Riedler I., Auprich M., Schips L., Salfellner M., Pummer K., Hubmer G. Did the rate of incidental prostate cancer change in the era of PSA testing? A retrospective study of 1127 patients // Urology. – 2003. – V. 62. – Р. 451–445.

Argyropoulos A., Doumas K., Farmakis A. et al. Characteristics of patients with stage T1b incidental prostate cancer // Scand. J. Urol. Nephrol. – 2005. – V. 39, N 4. – P. 289–293.

Kanno H., Umemoto S., Izumi K. et al. Prostate cancer development after transurethral resection of the prostate histopathological studies of radical prostatectoy specimens. // Nippon Hinyokika Gakkai Zasshi. – 2006. – V. 97, N 4. – P. 649–659.

Yoo C., Zhao Z., Ma W., Zeng G., Qi D. PSCA mRNA expression in preoperatively negative prostate biopsies predicts incidental prostate cancer in patients under going transurethral resection of the prostate for benign prostatic hyperplasia. – Department of Urology, Minimally Invasive Surgery Center, The First Affiliated Hospital, Guangzhou Medical College, Guangzhou, Guangdong Province, China.